Dana-Farber Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer
Sevabertinib, an oral targeted therapy, has gained FDA approval for adults with non-small-cell lung cancer (NSCLC) harboring specific HER2 mutations, marking a significant advancement in treatment options for an estimated 4,000 to 8,000 affected individuals annually in the U.S. Led by Dr. Matthew Meyerson from Dana-Farber Cancer Institute, the therapy effectively blocks abnormal HER2 signals and shows promise in clinical trials, with over half of participants experiencing tumor shrinkage. Future studies are exploring its use in various solid tumors.
1. Sevabertinib approved for non-small-cell lung cancer (NSCLC) with HER2 mutations. 2. Effective for patients who have had chemotherapy/immunotherapy. 3. Clinical studies show over half experienced tumor shrinkage. 4. New option for estimated 4,000-8,000 patients annually in the US. 5. It selectively blocks abnormal HER2 signals, limiting side effects. 6. Ongoing trials for first-line treatment for HER2-mutant NSCLC. 7. Advances research from Dana-Farber and Broad Institute.
Listen Tab content
